Discontinued cardiovascular drugs in 2013 and 2014

Bibliography

• WHO. Cardiovascular diseases (CVDs). 2015. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/ [Last accessed 27 March 2015]
   Google Scholar
• WHO. Cardiovascular disease. 2015. Available from: http://www.who.int/cardiovascular_diseases/en/ [ Last accessed 27 March 2015]
   Google Scholar
• Okokok. Cardiovascular Therapeutic Drugs: Technologies and Global Markets. 2010. Available from: http://www.okokok.com.cn/Htmls/PE_Product/100805/84271.html [ Last accessed 27 March 2015]
   Google Scholar
• Mori M, Hirata T, Ikeno A, et al. DSP-9599, a novel direct renin inhibitor, reduces renal injury in double transgenic rats over-expressing both human renin and angiotensinogen genes[Adstract PP.42.353]. 23rd Eur Meet Hypertens; June 14-17, Milan
   Google Scholar
• Ikeno A, Mori M, Kawai H, et al. A first-in-human, phase 1 study of DSP-9599, a novel direct renin inhibitor, with translational assessment in high-renin monkey[Abstract PP.20.162]. 23rd Eur Meet Hypertens; June 14-17, Milan) 2013
   Google Scholar
• Dainippon Sumitomo Pharma. Supplementary Financial Data for the Year Ended March 31, 2012. 2012. Available from: http://www.ds-pharma.com/ir/library/financial_results_summary/pdf/ebr20120510_2.pdf [Last accessed 12 March 2015]
   Google Scholar
• Dainippon Sumitomo Pharma. Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2013. 2013. Available from: http://www.ds-pharma.com/ir/library/financial_results_summary/pdf/ebr20130131_2.pdf [Last accessed 12 March 2015]
   Google Scholar
• Jenkins Y, Sun TQ, Li Y, et al. Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways. BMC Res Notes 2014;7:674
   PubMedGoogle Scholar
• Murray O; Robinson. Parkinson’s Disease Gene Networks. 2010. Available from: http://media.virbcdn.com/files/6d/78117666ecd66df9-PDGeneNetworksMolquant.pdf [Last accessed 13 March 2015]
   Google Scholar
• PR Newswire. Rigel Announces Publication Of R118 AMPK Activator Research. 2014. Available from: http://www.thestreet.com/story/12519501/1/rigel-announces-publication-of-r118-ampk-activator-research.html [Last accessed 23 March 2015]
   Google Scholar
• PR Newswire. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study. 2014. Available from: http://www.thestreet.com/story/12843148/1/r348-did-not-meet-endpoints-in-phase-2-dry-eye-study.html [Last accessed 23 March 2015]
   Google Scholar
• Wikipedia. Prostaglandin. 2014. Available from: http://en.wikipedia.org/wiki/Prostaglandin#cite_note-isbn0-87893-617-3-1 [Last accessed 6 March 2015]
   Google Scholar
• ONO PHARMACEUTICAL. Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue. 2011. Available from: http://www.ono.co.jp/eng/news/pdf/sm_cn110601.pdf [Last accessed 23 March 2015]
   Google Scholar
• Sumitomo Dainippon Pharma. Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue. 2013. Available from: http://www.ds-pharma.com/news/2013/20130125.html [Last accessed 6 March 2015]
   Google Scholar
• ONO PHARMACEUTICAL. Discontinuation of Development for an Additional Indication of Cervical Spondylosis of Limaprost Alfadex, an Oral Prostaglandin E1 Derivative Preparation. 2008. Available from: http://www.ds-pharma.com/pdf_view.php?id=145 [Last accessed 23 March 2015]
   Google Scholar
• Clinicaltrials.gov. The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy. 2014. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02125981?term=limaprost+alfadex&rank=1 [Last accessed 6 March 2015]
   Google Scholar
• Taisho Pharmaceuticals. Taking Resolute Steps in a Shifting Market Annual Report 2008. 2008. Available from: http://www.taisho-holdings.co.jp/ir/library/pdf/annual/08_all.pdf [Last accessed 6 March 2015]
   Google Scholar
• Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006;48(12):2539–45
   PubMed Web of Science ®Google Scholar
• Ishiwata N, Noguchi K, Kawanishi M, et al. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walkingdistance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. Life Sci 2007;81(21):970–8
   PubMedGoogle Scholar
• Clinicaltrials.gov. Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication. 2006. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00102050?term=nm-702&rank=1 [Last accessed 6 March 2015]
   Google Scholar
• Taisho Pharmaceutical Co Ltd. Second Quarter of FY2014. 2015. Available from: http://www.taisho-holdings.co.jp/en/ir/library/pdf/presentation/14_1031_01-e.pdf [Last accessed 3 April 2015]
   Google Scholar
• Taisho Pharmaceutical Co Ltd. Discontinuation of Development of NT-702 for a Part of Indications. 2009. Available from: http://www.taisho.co.jp/en/company/release/2009/2009082601-e.pdf [Last accessed 3 April 2015]
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin Announces the Development Status of Bardoxolone Methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in Japan. 2013. Available from: http://kyowa-kirin.com/news_releases/2013/e20131111_01.html [Last accessed 10 March 2015]
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin and Reata Pharmaceuticals entered into a licensing agreement on bardoxolone methyl in Japan and other selected Asian markets. 2010. Available from: http://kyowa-kirin.com/news_releases/2010/e20100108_01.html [Last accessed 10 March 2015]
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Future development direction for bardoxolone methyl (RTA 402). 2014. Available from: http://kyowa-kirin.com/news_releases/2014/e20140702_01.html [Last accessed 10 March 2015]
   Google Scholar
• Hong DS, Kurzrock R, Supko JG, et al.A Phase I. First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 2012;18(12):3396–406
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323(18):1234–8
   PubMed Web of Science ®Google Scholar
• Roche. Roche provides update on Phase III study of dalcetrapib. 2012. Available from: http://www.roche.com/media/store/releases/med-cor-2012-05-07.htm [Last accessed 10 March 2015]
   Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089–99
   PubMed Web of Science ®Google Scholar
• Japan Tobacco. JT’s Consolidated Financial Results for the 12 months ended March 31, 2012. 2012. Available from: http://www.jti.com/files/5413/3542/0077/FINAL_JTs_Consolidated_Financial_Results_for_the_12_months_ended_March_31_2012.pdf [Last accessed 10 March 2015]
   Google Scholar
• Tokyo. JT’s consolidated financial results for FY2013 first quarter. 2013. Available from: http://www.jt.com/media/press_releases/2013/pdf/20130730_02.pdf [Last accessed 23 March 2015]
   Google Scholar
• Lippiello PM, Beaver JS, Gatto GJ, et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008;14(4):266–77
   PubMed Web of Science ®Google Scholar
• Targacept, Inc. Targacept announces plans to develop enantiomer of mecamylamine as augmentation therapy for depression. 2007. Available from: http://www.medicalnewstoday.com/releases/86693.php [Last accessed 10 May 2015]
   Google Scholar
• Fedorov N, Moore L, Gatto G, et al. Differential effects of TC-5214[S-(+)-mecamylamine] and TC-5213[R-(-)-mecamylamine] at low and high sensitivity human alpha4beta2 nicotinic receptors and in animal models of depression and anxiety. TC 2007;100:150
   Google Scholar
• AstraZeneca. A Study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01197508?term=NCT01197508&rank=1 [Last accessed 23 March 2015]
   Google Scholar
• AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01180400?term=NCT01180400&rank=1 [Last accessed 23 March 2015]
   Google Scholar
• AstraZeneca. A study to assess the long- term safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01152554?term=NCT01152554&rank=1 [Last accessed 23 March 2015]
   Google Scholar
• AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01153347?term=NCT01153347&rank=1 [Last accessed 23 March 2015]
   Google Scholar
• AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder (MDD). 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01157078?term=NCT01157078&rank=1 [Last accessed 23 March 2015]
   Google Scholar
• Press Release. AstraZeneca and targacept announce remaining TC-5214 phase 3 efficacy studies do not meet primary endpoint, regulatory filing will not be pursued. 2012. Available from: http://www.targacept.com/newsroom/index.cfm?nid=AstraZeneca%20and%20Targacept%20Announce%20Remaining%20TC%2D5214%20Phase%203%20Efficacy%20Studies%20Do%20Not%20Meet%20Primary%20Endpoint%2C%20Regulatory%20Filing%20Will%20Not%20Be%20Pursued&newsyear=2012 [Last accessed 23 March 2015]
   Google Scholar
• Press Release. Targacept announces plans to develop TC-5214 in overactive bladder. 2012. Available from: http://www.targacept.com/newsroom/index.cfm?nid=Targacept%20Announces%20Plans%20to%20Develop%20TC%2D5214%20in%20Overactive%20Bladder&newsyear=2012 [Last accessed 23 March 2015]
   Google Scholar
• Press Release. Targacept announces initiation of phase 2b study of TC-5214 in overactive bladder. 2013. Available from: http://www.targacept.com/newsroom/index.cfm?nid=Targacept%20Announces%20Initiation%20of%20Phase%202b%20Study%20of%20TC%2D5214%20in%20Overactive%20Bladder&newsyear=2013 [Last accessed 23 March 2015]
   Google Scholar
• Press Release. Targacept to discontinue TC-5214 overactive bladder program. 2014. Available from: http://www.targacept.com/newsroom/index.cfm?nid=Targacept%20to%20Discontinue%20TC%2D5214%20Overactive%20Bladder%20Program&newsyear=2014 [Last accessed 23 March 2015]
   Google Scholar
• Press Release. Targacept reports second quarter 2009 financial results. 2009. Available from: http://www.targacept.com/newsroom/index.cfm?nid=Targacept%20Reports%20Second%20Quarter%202009%20Financial%20Results&newsyear=2009 [Last accessed 23 March 2015]
   Google Scholar
• Teijin. Consolidated financial statements summary. 2009. Available from: http://www.teijin.com/ir/library/consolidated_results/pdf/cr_091102.pdf [Last accessed 23 March 2015]
   Google Scholar
• John Carroll. BMS offers up to $385M to develop atrial fibrillation drug. 2009. Available from: http://www.fiercebiotech.com/story/bms-offers-385m-develop-atrial-fibrillation-drug/2009-03-05 [Last accessed 11 March 2015]
   Google Scholar
• Nissan Chemical Industries, Ltd. Annual report 2010 11. Available from: http://www.nissanchem.co.jp/ir_info/archive/ar/ar2010.pdf [Last accessed 11 March 2015]
   Google Scholar
• John Carroll. Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. 2013. Available from: http://www.fiercebiotech.com/story/isis-dumps-rheumatoid-arthritis-effort-after-antisense-drug-flunks-phii/2013-08-05 [Last accessed 12 March 2015]
   Google Scholar
• Roche. Media release. 2012. Available from: http://www.roche.com/media/store/releases/med-cor-2012-09-05.htm [Last accessed 13 March 2015]
   Google Scholar
• ClinicalTrials. A phase II study of the safety and efficacy of MPSK3169A in patients with coronary heart disease or high risk of coronary heart disease. 2012. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01609140?term=NCT01609140&rank=1 [Last accessed 13 March 2015]
   Google Scholar
• Roche. Pipeline summary. 2014. Available from: http://www.roche.com/irp2q14e-annex.pdf [Last accessed 13 March 2015]
   Google Scholar
• Zhang XS, Xiang BR. Discontinued drugs in 2007: cardiovascular drugs. Expert Opin Investig Drugs 2008;17(12):1817–28
   PubMed Web of Science ®Google Scholar
• Zhang XS, Xiang BR. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 2009;18(7):875–85
   PubMed Web of Science ®Google Scholar
• Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: cardiovascular drugs. Expert Opin Investig Drugs 2010;20(10):1311–25
   Web of Science ®Google Scholar
• Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2012: cardiovascular drugs. Expert Opin Investig Drugs 2013;22(11):1437–51
   PubMed Web of Science ®Google Scholar
• Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs 2012;21(10):1449–62
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711–16
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255–67
   PubMed Web of Science ®Google Scholar
• Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122(8):850–2
   PubMed Web of Science ®Google Scholar
• Vogel RA. PCSK9 inhibition: the next statin? J Am Coll Cardiol 2012;59(25):2354–5
   PubMed Web of Science ®Google Scholar
• Sanofi. Sanofi and regeneron present detailed positive results from four pivotal alirocumab trials at ESC Congress. 2014. Available from: http://en.sanofi.com/Images/37129_20140831_AlirocumabESCDataRelease_en.pdf [Last accessed 28 March 2015]
   Google Scholar
• AMGEN. Amgen announces positive top-line results from phase 3 TESLA trial of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia. 2014. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01609140?term=NCT01609140&rank=1 [Last accessed 28 March 2015]
   Google Scholar
• Randi Hernandez. Amgen Sues sanofi and regeneron over patent for mAb targeting PCSK9. 2014. Available from: http://www.biopharminternational.com/amgen-sues-sanofi-and-regeneron-over-patent-mab-targeting-pcsk9 [Last accessed 28 March 2015]
   Google Scholar
• Sanofi. Sanofi and Regeneron Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA. 2015. Available from: http://en.sanofi.com/Images/38242_20150226_alirocumabbla_en.pdf [Last accessed 28 March 2015]
   Google Scholar
• AMGEN. Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan. 2015. Available from: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2027353 [Last accessed 28 March 2015]
   Google Scholar